Canopy featured in the St. Louis Business Journal! Read all about us here. “Canopy Biosciences, a young startup looking to accelerate the commercialization of life science reagent tools and services, has raised $2 million from investors.” Canopy looks to in-license — essentially a collaboration agreement between two parties in which one company performs the R&D […]
Read more
Full speed. Half speed. Full stop. Those are the usual choices for controlling the amount of protein produced from a particular gene. Other speeds are possible, but they typically require a lot of effort on the part of scientists, who often resort to the identification and exploitation of a hypomorphic mutation, that is, a mutation […]
